Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy

• Published in: Therapeutic Advances in Chronic Disease Vol. 9; no. 9; pp. 159 - 170
• Main Authors: Ariëns, Lieneke F.M., Bakker, Daphne S., van der Schaft, Jorien, Garritsen, Floor M., Thijs, Judith L., de Bruin-Weller, Marjolein S.
• Format: Book Review Journal Article
• Language: English
• Published: London, England SAGE Publications 01.09.2018; SAGE PUBLICATIONS, INC
• Subjects: Dermatitis; Eczema; Immunotherapy; Medical research; Monoclonal antibodies; Pathogenesis; Pharmacology; Review; interleukin-4; atopic dermatitis; biologics; systemic treatment; interleukin-13; dupilumab
• ISSN: 2040-6223; 2040-6231
• DOI: 10.1177/2040622318773686

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The prevalence of AD is increasing and is currently estimated at 10–20% in adults worldwide. In the majority of patients, AD can be adequately controlled with topical treatment or ultraviolet light therapy, but there is a high unmet need for effective and safe therapeutics in patients with more severe or difficult to treat AD. During the past decade, new advances in the understanding of the underlying immune pathogenesis of AD have led to the development of new, more targeted therapies. Dupilumab, a fully human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking the IL-4 and IL-13 pathway, is one of the first biologics that has been developed for AD. Dupilumab has shown promising results in phase III trials and has recently been approved by the US Food and Drug Administration and the European Commission for the treatment of moderate to severe AD. With the approval of dupilumab, we are entering a new era of biological therapeutics in AD management. The place of dupilumab should be established in the current treatment standards. Based on current treatment guidelines and experts’ opinions in the management of AD, we have built a proposal for a treatment algorithm for systemic treatment of AD in European countries.